Loading stock data…
$4.86-0.24 (-4.75%)
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. in the Healthcare sector is trading at $4.86 with a market capitalization of $9M. Wall Street consensus targets $25.00 (1 analysts), implying a +414.9% move over the next 12 months. The stock is currently 39% below its 52-week high of $8.00, remaining 1.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.48M↑ | -$2.17M↓ | -$1.62M↓ | -$1.37M↓ | -$1.30M |
| Net Income | $159,944↑ | -$1.31M↑ | -$3.17M↓ | -$1.60M↓ | -$1.23M |
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio fr...